Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04854304 · ClinicalTrials.gov registry record
Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts
A clinical trial of Breast Diseases, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT04854304 is a study of Breast Diseases that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 500 participants, above the 255-participant average among 8 other Breast Diseases trials with a reported enrollment target (96% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04854304, a study of Breast Diseases, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
500 patients will be prospectively recruited to undergo a fast breast MRI examination. The women will be recruited for the study will meet the following criteria: 1. African American 2. negative DBT examination 11 months prior to recruitment 3. Heterogeneously and Extremely breast densities 4. clinically asymptomatic- no palpable masses, focal thickening or clinically significant discharge. Investigators will identify these patients EPIC database utilizing the date of their last mammogram. Interested patients may contact our research coordinators by the phone number provided in the recruitment materials. The study recruitment information will also be shared with referring physicians. Physicians may also directly refer patients to the study.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Fast Breast Abbreviated Magnetic Renounce Imaging
Study Locations (1)
Pennsylvania
- UPENN - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2021-09-23 |
| Est. Completion | 2028-07-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04854304
The ClinicalTrials.gov registry entry for NCT04854304 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 255-participant average among 8 other Breast Diseases trials with a reported enrollment target (96% higher). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Diseases appearing as the primary indexed condition, and to 1 intervention - of which Fast Breast Abbreviated Magnetic Renounce Imaging is the first listed.
NCT04854304 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04854304 about?
NCT04854304 is a clinical study titled "Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts". 500 patients will be prospectively recruited to undergo a fast breast MRI examination. The women will be recruited for the study will meet the following criteria: 1. African American 2. negative DBT examination 11 months prior to recruitment 3. Heterogeneously and Extremely breast densities 4. clini...
What is the current status of trial NCT04854304?
This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2021-09-23. Estimated completion is 2028-07-13.
What conditions does trial NCT04854304 study?
This clinical trial studies the following conditions: Breast Diseases.
What interventions are being tested in trial NCT04854304?
The interventions under investigation include: Fast Breast Abbreviated Magnetic Renounce Imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04854304?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04854304 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RECRUITING · Phase 1
-
A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
RECRUITING
-
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
ACTIVE NOT RECRUITING · Phase 3
-
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
ACTIVE NOT RECRUITING · Phase 1
-
Lesion Detection of Automated Breast Ultrasound Compared With Handheld Physician-performed Breast Ultrasound
COMPLETED · NA
-
Dotarem vs Gadobutrol Contrast for Breast MRI
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.